Pharminent

Expert Discusses 2-Year Nivolumab Data and Other Immunotherapy Developments in NSCLC

Hossein Borghaei, DO, discusses the significance of the 2-year follow-up results, the evolving role of PD-L1 as a biomarker and others that are in development, and emerging immunotherapy agents in the field of non–small cell lung cancer. http://www.onclive.com/web-exclusives/expert-discusses-2-year-nivolumab-data-and-other-immunotherapy-developments-in-nsclc

Filed under: Cancer, Immunotherapy